Hilde Windels is a member of the Board of Directors of Biocartis, Ablynx, Erytech, Mycartis, MDx Health and VIB. From March to September 2017, she was CEO of Biocartis, previously and since October 2015, Deputy CEO and Managing Director of Biocartis, and before that CFO of Biocartis since 2011. She has almost 20 years of experience in the biotech sector with a track record in building and structuring organizations, fundraising, Mergers & Acquisitions, public capital markets and business & corporate strategy.
From 2009 to mid-2011 she worked as an independent CFO for various private biotech companies. From 1999 to 2008, she was the CFO of Devgen, a listed company. She was also a member of the board of directors of Devgen and FlandersBio.
Hilde Windels obtained the diploma in Commercial Engineering (KU Leuven).